House orphan drug bill
Rep. Studds (D-Mass.) and Energy & Commerce/Health subcommittee Chairman Waxman (D-Calif.) introduce companion legislation (HR 4959) on April 9 to Senate measure S 2060. Studds proposed a bill last year with a $150 mil. sales "trigger" for orphan drugs, after which FDA could consider marketing applications from competitors; changes in the new bill include adoption of S 2060's $200 mil. trigger....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth